Biondo Investment Advisors LLC Sells 2,336 Shares of AbbVie Inc. $ABBV

Biondo Investment Advisors LLC cut its position in AbbVie Inc. (NYSE:ABBV) by 3.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 76,248 shares of the company’s stock after selling 2,336 shares during the quarter. AbbVie comprises about 2.1% of Biondo Investment Advisors LLC’s portfolio, making the stock its 11th biggest holding. Biondo Investment Advisors LLC’s holdings in AbbVie were worth $17,422,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ABBV. Chelsea Counsel Co. bought a new stake in AbbVie in the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the 4th quarter valued at $28,000. Westend Capital Management LLC bought a new stake in AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter valued at $31,000. Finally, Legacy Wealth Managment LLC ID boosted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on ABBV. Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Royal Bank Of Canada began coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a research report on Thursday, April 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Price Performance

Shares of AbbVie stock opened at $227.54 on Friday. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81. The stock’s 50-day moving average is $211.05 and its 200 day moving average is $219.07. The firm has a market cap of $402.02 billion, a price-to-earnings ratio of 112.09, a PEG ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts expect that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.